SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Exelixis, Inc. (EXEL)
An SI Board Since January 2001
Posts SubjectMarks Bans Symbol
930 66 0 EXEL
Emcee:  kinkblot Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
105Exelixis Files IND Application for Novel Anticancer Compound XL880 Thursday Decescaram(o)uche-12/16/2004
104GS: EXEL(IL/N): More visibility on broad pipeline & new alliances in 2005. mopgcw-11/30/2004
103<i>3Q: Burn rate too high, imo.</i> Wait 'till next year. Be Hkeokalani'nui-11/8/2004
1023Q: Burn rate too high, imo. Miljenko Exelixis Announces Third Quarter 2004 FiMiljenko Zuanic-11/8/2004
101>> Please, NO DEBT! << Second that. Keep it clean. Dilute the crascaram(o)uche-10/27/2004
100Please, NO DEBT!keokalani'nui-10/27/2004
99Exelixis Files Universal Shelf Registration Statement Wednesday October 27, 6:04mopgcw-10/27/2004
98Piper: EXEL :Initiates Phase I Trial of XL999 in Solid Cancer 2004-10-25 09:30 mopgcw-10/27/2004
97Exelixis Initiates Phase 1 Clinical Trial for XL999 06:01 Monday, October 25mopgcw-10/25/2004
96GS: Gilead Sciences Inc. EPS (FY Dec) 2004E $0.88, 2005E $1.08 Outperform/Neutrmopgcw-10/25/2004
95<<<Two observations: 1. Interviewed Garnier (GSK) a while back. He is prkrw-10/6/2004
94Can't think of why there would be more than one, apart from McEnvy. (and itscaram(o)uche-10/6/2004
93MP inhibitors Thanks for thoughts. Rick- surely there's only one mcknucklf_mcknuckles-10/6/2004
92>> company line almost never registers. << GLIA disease. Go Twins!scaram(o)uche-10/5/2004
91yes, MMPs are a focus of a few well-brained outfits, and I know the story re. coscaram(o)uche-10/5/2004
90I probably know a great deal less about MMPs than you... but I thought a quite anigel bates-10/5/2004
89Company line, paraphrased: All other MMP candidates have failed b/c of therapekeokalani'nui-10/5/2004
88THE mcknuckles? Man, that sets some sort of record for lurking. ;-) MMPs.... scaram(o)uche-10/5/2004
87Any opinions on EXEL's MP inhibitor? I thought MP inhibitors as a class haf_mcknuckles-10/5/2004
86Exelixis Releases Pre-Clinical Data on Two Spectrum Selective Kinase Inhibitors scaram(o)uche-9/30/2004
85<i>Our price target of $10 is based on 13x FY04 revenues</i> I justkeokalani'nui-9/29/2004
84Piper (I wonder why they bother?): Exelixis Acquires X-Ceptor KEY POINTS: * Exmopgcw-9/29/2004
83GS: EXEL (IL/N): Acquisition of X-Ceptor positive long-term. Maintain est. 52-Wmopgcw-9/28/2004
82Dr. R Evans' name comes up in the CC. Lasker Award for just this sort of stkeokalani'nui-9/28/2004
81From the PR. Obviously the website was not a priority for xceptor: The companykeokalani'nui-9/28/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News